Kazutaka Sunami

14PUBLICATIONS
36CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapyStatistical data scienceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Dec 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Seguro

|May 09, 2025
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM.

Shinsuke Iida, Kazutaka Sunami, Shigeki Ito

|Dec 24, 2024
DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.

Kazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada

|Nov 28, 2024
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.

Tadao Ishida, Yoshiaki Kuroda, Kosei Matsue

|Mar 18, 2024
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.

Yasuo Mori, Jun Takizawa, Yuna Katsuoka

|Jul 18, 2023
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.

Kotaro Shide, Katsuto Takenaka, Akira Kitanaka

Pageof 3

Frequent Collaborators

3 joint publications

Shinsuke Iida

2 joint publications

Junichiro Yuda

2 joint publications

Tadao Ishida

1 joint publications

Takehiko Mori